TOP PICK
Amgen Inc.
Granddaddy of biotech. Even better than it used to be. Very deep bench of drugs. New acquisition will add growth on top of already-decent growth. Very strong financials. Income opportunity, stability, and some growth not yet fully priced in. Yield is 3.14%, well covered at 42%, increased by 11% average annually over 5 years. (Analysts’ price target is $268.80)
biotechnology / pharmaceutical
BUY
Amgen Inc.
Share have given up a lot since its Horizon Therapeutics deal, making it an opportunity.
biotechnology / pharmaceutical
BUY
Amgen Inc.
Today, they said they are buying Horizon Therapeutics for $27.8 billion. This deal should close quickly, since there's little overlap of these companies' drugs. Initially, he thought the price was high, but now he likes the deal. An established, big biotech that bought a younger biotech with exciting drugs at a 15% premium. Amgen wants HT's portfolio of drugs treating rare diseases and well-covered by insurance, therefore lucrative. HT's drugs will benefit from Amgen's worldwide distribution.
biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 01/21, Up 20%) Bought it to be defensive for 2022. They announced a new facility in San Francisco. The future looks positive.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 03/20, Up 4.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN has triggered its stop at $228. To remain disciplined, we recommend covering the holding at this time.
biotechnology / pharmaceutical
BUY
Amgen Inc.
Some of their key drugs are coming off patent, so he likes how they're making key buys of companies like CCXI, which would give Amgen exposure to drugs for auto-immune diseases and inflammatory conditions. CCXI has one drug on the market to treat blood vessel inflammation and a handful of phase 1 treatments including ulcerative colitis. The deal is good for Amgen.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 03/20, Up 17.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN is progressing well. We now recommend trailing up the stop (from $218) to $228.
biotechnology / pharmaceutical
TOP PICK
Amgen Inc.
Are big worries about inflation and the economy and war. So, be in the US dollar, which should rally if the world goes deflationary. This is also a big name, and there's a massive rotation into the drug companies. He target $272. It pays a 3% dividend. (Analysts’ price target is $242.24)
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Amgen Inc.
(A Top Pick Nov 03/20, Up 7.8%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with AMGN is progressing well. To remain disciplined, we now recommend trailing up the stop (from $205) to $218.
biotechnology / pharmaceutical
TOP PICK
Amgen Inc.
This name has been beaten up and now offers value. There is concern that markets could experience a pull-back and one way to play that is this one. It is a large entity in the healthcare space and has under-performed its space. As we push out of the pandemic we are going to see increased regular appointments and more diagnostics. This company offers decent value. (Analysts’ price target is $243.05)
biotechnology / pharmaceutical
WAIT
Amgen Inc.
It has been under-performing the overall market. Biotechs don't do well at this point seasonally. Its seasonal period starts in June and the trade could setup quite well. Don't look at it at this time.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Amgen Inc.

Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)

biotechnology / pharmaceutical
WATCH
Amgen Inc.
A pure biotech company with a strong biosimilar business with a great core franchise in immunology. Their oncology business is also robust. They had a recent miss in one of their trials, which was the second miss this year. (There is another phase 3 trial this year.) He wants to see either more execution on their R&D drugs or backfill through some M&A in coming years. He's closely watching this.
biotechnology / pharmaceutical
BUY
Amgen Inc.
It has a lot of irons in the fire including an oncology franchise they're not getting any credit for.
biotechnology / pharmaceutical
Showing 1 to 15 of 117 entries

Amgen Inc.(AMGN-Q) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 8

Stockchase rating for Amgen Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Amgen Inc.(AMGN-Q) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q

Is Amgen Inc. a buy or a sell?

In the last year, 8 stock analysts published opinions about AMGN-Q. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Amgen Inc. worth watching?

8 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2023-02-03, Amgen Inc. (AMGN-Q) stock closed at a price of $245.17.